Introduction
Efficient gene transfer in Ͼ10% of repopulating hematopoietic stem cells (HSCs) can be achieved using retroviral vectors, as indicated by xenotransplantation of human peripheral blood stem cells in NOD/SCID mice, 1 and shown after bone marrow transplantation (BMT) in non-human primates and clinical studies. 2, 3 Even if higher marking rates could be achieved by the improvement of cell culture conditions or vector systems, gene transfer efficiency should still be limited to inserting not more than one or two vector copies, regarding the risk of insertional mutagenesis of cellular alleles. 4 This implies that gene transfer frequency should not exceed 50% of an unselected graft. 5 Interindividual variability of transgene chimerism and silencing of transgene expression over time still represent important impediments for the development of hematopoietic gene therapy. 3, 6, 7 Unselected gene-modified HSCs compete with unmodified counterparts for engraftment and hematopoietic activity. Further loss of cells with the transgenic phenotype may result from downregulation or complete extinction (silencing) of the recombinant allele. Transgene expression is not only dependent on its cis-active control elements, but also on the insertion site which cannot be controlled with available vector systems. 8 In hematopoietic gene therapy, neither appropriate cis-active elements supporting persisting multilineage gene expression in vivo nor supportive integration sites have been identified, because all studies available showed either inconsistent gene expression of transplanted cells, or presented a population analysis of different clones of HSCs, often containing multiple vector insertions per genome. Therefore, limited insights have been achieved into the mechanisms underlying persistent gene expression in vivo.
In the mouse, retroviral transgene silencing manifests primarily upon serial BMT, 6 but has also been observed within the first 6 weeks following primary BMT of HSCs. 9 In the latter situation, transgenes escaping silencing have been shown to maintain expression in the myeloid progeny of HSCs, and to a lesser extent in lymphoid lineages. Mature erythroid cells or platelets have not been evaluated. Other studies have sorted cells prior to primary BMT, either by flow cytometry [9] [10] [11] [12] [13] [14] or immunoaffinity selection, 15 showing that both procedures increase the likelihood for obtaining active transgene expression in vivo. Despite selection prior to BMT, all but one study published to date resulted in an incomplete and variable transgene chimerism. 9, 10, [12] [13] [14] [15] The single study with virtually complete expression in multiple lineages 11 did not show data regarding reconstitution of secondary recipients, hematopoietic clonality or transgene copy number. Thus, it remained unclear whether single retrovirally transduced HSCs are capable of multilineage transgene expression in vivo. This concern is substantiated by studies performed in cloned immortalized hematopoietic cells in vitro, demonstrating inconsistent expression with a high frequency of silencing (ෂ80%) from conventional retroviral vectors, either with or without selection. 16, 17 In reported cases of clonal retrovirally marked hematopoiesis, no multilineage analysis of transgene expression was available. 18, 19 Selecting HSCs with active transgene expression in vivo would circumvent these problems only when the HSCs expressing the transgene at the time of selection would continue to do so in the absence of selection and through subsequent clonal amplification and differentiation. Selection procedures applicable in vivo are based on the transfer and expression of genes mediating resistance to cytotoxic drugs, 3, [20] [21] [22] [23] encoding artifical signal transfer molecules, 24 or providing an inherent growth advantage. 25 If operative at the level of the HSCs and applied with high stringency, these selection procedures should result in completely transgenic hematopoiesis. This has been demonstrated using mutants of the DNA-alkyltransferase MGMT, which reverse lesions induced by DNA-alkylating agents. [21] [22] [23] However, in these cases either the multineage analysis of transgene expression following selection was incomplete, the retroviral copy num-Leukemia ber remained unclear or was high, or the clonality of reconstitution and multilineage expression in secondary recipients remained unclear. Moreover, the use of mutagenic selective agents generates formal problems in the interpretation of the results achieved. The other procedures used for in vivo selection either generated an inconsistent and unstable chimerism 10, 24 or were associated with polyclonal expansion mediated by an overexpressed transcription factor that by itself could have an impact on transgene expression. 25 The present study demonstrates that single HSCs expressing the transgene in vivo from a retroviral vector introduced at a low copy number can give rise to serial repopulation with persisting expression in diverse multipotent, myeloid, lymphoid, erythroid and megakaryocytic lineages. To achieve this, we used simple retroviral vectors containing long terminal repeat (LTR) sequences selected for high transcriptional activity and lacking dominant silencer motifs. 26 Two variants of the human CD34 (hCD34) antigen served as transgenic cell-surface markers, either the full-length cDNA (flCD34) encoding the complete intracellular signal transduction domain, or tCD34, its signaling-defective splice variant. 27 A single nontoxic immunoaffinity selection of retrovirally marked repopulating cells was applied to enrich for HSCs with active transgene expression in vivo prior to serial BMT.
Materials and methods

Vector production
The retroviral vectors used in this study contain the LTR of a variant of mouse spleen focus-forming virus (SFFVp) and the untranslated leader region derived from murine embryonic stem cell virus (MESV), deprived of viral coding sequences. 5, 26 SFa11tCD34 and SFa11flCD34 contain the coding sequences for human tCD34 and flCD34, respectively, under transcriptional control of the LTR. 26 SFa11EGFP is a similar vector encoding enhanced green fluorescent protein (EGFP). 5 Cellfree high-titer supernatants containing the vesicular stomatitis virus glycoprotein were generated as previously described. 5, 27, 28 
Mice and bone marrow transplantation
Animal experiments were approved by the local ethical committee. C57Bl/6J mice were kept in the animal facility of the Heinrich Pette Institute. Bone marrow (BM) cells were prepared, cultured and retrovirally transduced as previously described, [26] [27] [28] using a multiplicity of infection (MOI) of one infectious particle per cell, as calculated from previous titration of supernatant aliquots on SC-1 fibroblasts. Three transductions were performed within 48 h. One day after the final transduction, ie on the 5th day of ex vivo culture, cells were transplanted by tail vein injection into lethally irradiated (10 Gy) female recipients (n = 6 for each vector, aged 3 months) at a dose of 2.2 × 10 6 /mouse in the first cohort. Second cohort animals received 1 × 10 6 mononuclear BM cells per recipient, obtained from a pool of BM harvests combining all donors of one vector group. Immunoaffinity enrichment of hCD34 + mouse BM cells was achieved using the hCD34 progenitor cell isolation kit (Miltenyi Biotec, BergischGladbach, Germany) according to the manufacturer's instructions. 27 After enrichment, cells were stained with PE-coupled anti-CD34 (HPCA-2), not interfering with antibodies used for enrichment. Third cohort animals received 1 × 10 6 cells from individual secondary recipients per recipient, without prior selection.
CFU-S assay
Mononuclear BM cells (5 × 10 4 to 5 × 10 5 ) harvested from secondary recipients were transplanted by tail vein injection in lethally irradiated (10 Gy) recipients. After 12 days, wellisolated spleen colony-forming units (CFU-S) were dissected from spleens. Cells were suspended by passing them through a G18 needle and subjected to preparation of genomic DNA or FACS analysis for transgene expression.
Analysis of transgene expression
Expression of retrovirally transduced hCD34 was measured by flow cytometry, using monoclonal anti-CD34 antibodies HPCA-2 (Becton Dickinson, Heidelberg, Germany) or QBEND 10 (Coulter-Immunotech, Marseille, France), as previously described. 27 Cells were analyzed on a FACSCalibur instrument using Cellquest software (Becton Dickinson). After lysis of red blood cells (RBCs) in buffer containing NH 4 Cl, white blood cells (WBCs) from peripheral blood were costained with FITC-or APC-labeled mouse lineage-specific monoclonal antibodies B220, CD19 (B cells), CD11b, Gr-1 (myeloid cells), CD3e, NK1.1 (NK cells), or a combination of CD4 and CD8 (T cells). BM progenitors were distinguished using monoclonal antibodies Sca1, mCD34, or Ter119 (Pharmingen, Hamburg, Germany). Dead cells were excluded by propidium iodide staining. FACS analysis of transgene expression in red blood cells (RBCs) and platelets (PLTs, CD41 + ) followed the manufacturer's instructions (Becton Dickinson).
Southern blot
Genomic DNA was harvested from unseparated BM or single CFU-S using the QIAamp blood kit (Qiagen, Hilden, Germany). DNA was digested using the restriction enzymes indicated in Results, and Southern blots were performed according to standard protocols. 27 Membranes were probed with radioactively 32 P-labeled flCD34.
Statistical analysis
Numerical data are expressed as mean values with standard deviations. The Student's t-test (two-sided) was applied for unpaired samples, assuming equal variance. Differences with P Ͻ 0.05 were considered statistically significant.
Results
Overall stable transgene expression with pronounced interanimal variability in the first cohort
An overview of the design of the study and the vectors used is shown in Figure 1 . BM cells were transduced with VSVpseudotyped, replication-defective retroviral vectors expressing either human tCD34 or flCD34. The MOI was adjusted to Overview of vectors and experimental strategy. (a) All expression vectors used in the present study had identical control elements (SFFVp LTR, MESV leader 11). All cDNAs were inserted using unique restriction sites NotI and HindIII. (b) Schematic demonstration for experimental strategy. After 2 days of retroviral transduction, cells were engrafted into lethally irradiated recipients, which were observed for 28 weeks (28w). The second cohort received either immunoselected or unselected cells and was observed for 22 weeks (22w). In addition, bone marrow cells from some secondary recipients were transplanted into tertiary recipients.
obtain equivalent marking efficiencies, and to limit the expected integration frequency per clone to one or two, resembling clinical conditions. First cohort control animals received BM cells transduced with an identical vector used at a similar MOI which contained EGFP instead of flCD34 or tCD34. A first phenotypic analysis performed 8 weeks post transplantation revealed almost identical multilineage marking with tCD34, flCD34, and EGFP. Results obtained up to this point of the investigation have been published. 27 Twenty-eight weeks after BMT, when hematopoiesis is dependent on long-term repopulating HSCs, mice were killed for analysis of blood and BM cells. Flow cytometry data summarized in Table 1 (Table 1) , suggesting a stronger stability of the encoded protein or a longer half-life of marked cells. In all three experimental groups (tCD34, flCD34 and EGFP), a moderate increase in the frequency of marked cells was observed between weeks 6 and 28 following BMT ( Figure 2 ). As testing for contamination with replication-competent retrovirus was negative (data not shown), this indicated a superior marking of long-term repopulating cells. Taken together, these results indicated that the markers used allowed the analysis of multilineage transgene expression with similar sensitivity and that none of these had a strong effect on engraftment, expansion and differentiation of the transplanted cells.
Immunoaffinity selection of donor cells mediates complete functional transgene chimerism
To investigate whether purified HSCs expressing the retroviral transgene in vivo would give rise to a completely transgenic hematopoiesis, BM cells of primary recipients were pooled according to vector groups for subsequent immunoselection. Cells expressing hCD34 were enriched using MACS immunoaffinity columns, yielding a purity of 95% for cells engineered to express tCD34 and 96% for those expressing flCD34. The recovery of BM cells expressing transgenic CD34 was about 36% for tCD34 and 61% for flCD34. Second cohort animals received either MACS-enriched cells with complete transgene chimerism (group S) or unselected BM cells with incomplete transgene chimerism (group U). Immunoselection for transgene expression had no overt negative effect on the reconstitution of hematopoiesis. After secondary BMT, one death occurred in the repopulation phase (within 10 weeks) in each group U, both cases unavailable for necropsy. A single death in recipients of flCD34 + selected cells occurred after repopulation (week 22) and was not associated with disturbed hematopoiesis, as confirmed by histopathology of hematopoietic tissues. All surviving secondary recipients had normal blood cell counts when examined 8 and 22 weeks post BMT (50 weeks post gene transfer), irrespective of the transgene present. Mice killed 22 weeks post secondary BMT also had normal myelograms. A slightly increased ratio of myeloid to erythroid progenitors was noted in some mice, but none presented signs of preleukemia or leukemia (data not shown).
Recipients of immunoselected cells showed a remarkably high incidence of transgene expression. Frequencies approached 99% in RBCs, both with flCD34 and tCD34 (Table 2, Figure 2b ). Similar high levels were observed in WBCs of the peripheral blood and their sublineages such as CD11b + myeloid cells, B220 + B cells, and even in T cells expressing CD4 or CD8 (Table 3) . BM cells showed almost complete marking in the erythroid compartment (Ter119 + ). However, more primitive progenitors expressing Sca1 were less efficiently marked (around 70%), possibly due to the lower activity of retroviral LTRs in more primitive cell types, 26, 28 and/or reflecting a limited sensitivity of the detection method. The results were almost identical and thus highly reproducible when comparing the two different variants of CD34 (Tables 2 and 3) .
Importantly, recipients of unselected cells showed a decline in the marking efficiency over time, both with flCD34 or tCD34 (Table 2, Figure 2c and d), strongly arguing against a selective advantage mediated by the expression of the marker genes or the insertion of the vector. Frequencies of marked (Tables 1  and 2 ). cells at week 22 ranged from 18 to 67% of those observed in week 8. The decline reached statistical significance in RBCs of the tCD34 cohort (P = 0.0017, Table 2 ). However, after immunoselection expression persisted at high levels (87-105%, Table 2 ). The interanimal variability of transgene expression frequencies was greatly reduced in recipients of immunoselected cells (generally Ͻ5%), compared to recipients of unselected cells (generally ϾϾ50%). This resulted in a highly significant increase in marking frequency after immunoselection for all cell types and time points analyzed (P Ͻ 0.01).
Monoclonal or biclonal reconstitution of hematopoiesis in recipients of immunoselected cells
Given a transplant dose of 10 6 BM cells and an expected low frequency of long-term repopulating cells in primary recipients of retrovirally engineered HSCs, 18 ,19 the homogenous transgene expression after immunoselection was expected to originate from limited numbers of transduced clones. To address clonality, Southern blot analysis was performed using genomic DNA from BM cells harvested at the end of the second cohort (Figure 3 ). Digestion with PstI revealed the expected genome size of the retroviral vector, indicating that the great majority of transgenes were not rearranged. Digestion with HindIII or BglII, both cutting only once within the vector genome (Figure 1 ), showed predominant bands of individual clones in recipients of immunoselected cells. Some of these were shared by different secondary recipients, clearly demonstrating expansion of marked clones in primary recipients (Figure 3b ). Two pairs of mice even showed identical results (mice S3 and S5 of the flCD34 group S as well as mice S1 and S5 of the tCD34 group S). In total, only six different bands were distinguished in the five mice of the flCD34 group S, and five bands in the six mice of the tCD34 group S (Figure  3a and b) , revealing that most mice had monoclonal or biclonal hematopoiesis. According to the Southern blot of spleen DNA (Figure 3a and b) and further resolution in teriary CFU-S (Figure 3c and data not shown), monoclonal hematopoiesis with a single transgene insertion dominated in at least two mice (tCD34S#1 and tCD34S#5). Monoclonal hematopoiesis with two transgene insertions was observed in two other mice (flCD34#3 and flCD34#5, Figure 3c ). Donor tCD34#S4 showed a minor contribution of a clone with two insertions (1/10 clones) within a predominance of one clone with a single vector integration (9/10 clones analyzed). Donor flCD34#S1 had at least two marked clones, each showing one integration site (Figure 3c) . One of the eight CFU-S analyzed from this donor was not marked, indicating that the slightly reduced marking efficiency observed in this donor (ෂ80% of WBC were hCD34 + ) could be explained by the presence of competing untransduced cells.
In contrast, most recipients of unselected cells (including first cohort animals) showed no prominent bands. Prominent clonal bands were detected in only one out of five secondary recipients of tCD34 unselected cells, one out of three secondary recipients of flCD34 unselected cells, and two out of six primary recipients of flCD34 unselected cells (data not shown). This suggested that, compared with the recipients of unselected cells, the clonal repertoire of hematopoiesis was reduced after reconstitution with immunoselected cells, and established a perfect basis to evaluate the progeny of single clones. 
No evidence for transgene silencing in recipients of immunoselected cells
To distinguish whether the limited number of bands detected represented single clones with several integration sites, or different clones, and whether untransduced hematopoietic cells were still present, tertiary CFU-S of clonal origin were generated. We also determined by FACS whether these cells (CFC-S) still expressed the marker protein, allowing a clonal and subclonal assignment of transgene expression or silencing. Clones selected by MACS prior to secondary BMT did not show transgene silencing in tertiary CFU-S; all genetically marked clones analyzed in the CFU-S assay (n = 21) also expressed hCD34. Among the three mice chosen for CFU-S analysis, we recovered three of the six bands observed in the flCD34 group S and two of the five bands observed in the tCD34 group S. Within nine singly marked clones of identical origin, the subclonal variegation of transgene expression observed in the FACS analysis was only moderate (the mean fluorescence intensity ± standard deviation (s.d.) of hCD34 expression was 43.7 ± 6.4 arbitrary units), which was consistent with the low interanimal variability observed previously in secondary recipients. These results showed that mono-or biclonal hematopoiesis dominated in secondary recipients of immunoselected cells, all showing persistent multilineage transgene expression with similar high efficiency (Tables 2  and 3 , and Figure 3b ).
Clonal competition and transgene silencing in recipients of unselected cells
In clear contrast to the results obtained with immunoselected cells, tertiary CFU-S originating from secondary recipients of Leukemia unselected cells showed evidence for transgene silencing. Recipient tCD34#U5 had 5.9% hCD34 + PB cells 22 weeks after BMT, and showed three different clones in an analysis of 23 tertiary CFU-S. However, only one tertiary clone still expressed hCD34. Similarly, recipient tCD34#U1 which had 19.4% hCD34 + PB cells 22 weeks after BMT, showed two different clones in an analysis of 11 tertiary CFU-S. Again, only one of these still expressed hCD34.
In addition to transgene silencing, we also noted a significant contribution of untransduced clones to the mixed and inconsistent chimerism in recipients of unselected cells. For example, secondary recipient flCD34#U3, which had 4.8% hCD34 + PB cells 22 weeks after BMT, showed no transgene insertion in all 12 tertiary CFU-S analyzed (data not shown). These data revealed that the decrease of transgene expression frequencies observed in recipients of unselected cells was due to both silencing of transduced clones and overgrowth with untransduced cells.
It was interesting to note that all transduced tertiary CFU-S detected in recipients of unselected cells had only one transgene integration, whereas clones with two insertions were found in recipients of selected cells. This suggested that immunoselection enriched cells with higher transgene copy number (possibly resulting in stronger transgene expression). In line with this hypothesis, hCD34 expression levels were higher in CFU-S originating from selected cells as opposed to those derived from unselected cells (data not shown). This observation not only indicated that immunoselection enriched for clones expressing relatively high levels of the transgene in repopulating HSCs, but also implied that stem cell clones with high transgene expression in vivo maintain an active transgene during multilineage differentiation and through serial BMT.
Figure 3
Monoclonal or oligoclonal hematopoiesis after immunoselection. Southern blot of genomic DNA from BM cells of secondary cohort animals (a, b) or from CFC-S of tertiary cohort animals (c). DNA was digested with restriction enzymes HindIII, PstI or BglII, as indicated. The membrane was hybridized with the flCD34 cDNA as a probe. S1 etc., mouse 1 from secondary recipients of immunoselected cells. DNA from negative control mice (NC) is shown for comparison, revealing crosshybridization of endogenous sequences. All other bands result from retroviral vector integrations. Longer exposure of the film showed that CFU-S #1 derived from mouse flCD34#S3, shown in (c), had an identical integration pattern as the other clones derived from the same donor. M, molecular weight standard.
Persisting transgene expression in tertiary recipients after a single immunoselection step
The CFU-S assay is an established model to detect clonality and transgene silencing through serial BMT. However, this assay does not provide an accurate read-out for long-lived stem cells with the capacity for serial multilineage reconstitution. Therefore, we repopulated tertiary recipients with the BM cells remaining after the extensive analysis described above (hematology status, FACS, Southern blot, CFU-S). Although gene-marked cells were not enriched prior to tertiary BMT, transgene expression persisted at a high frequency in five out of six mice observed up to 47 weeks post BMT, equivalent to 97 weeks post gene transfer (Figure 4) . In this experiment, we also demonstrated hCD34 expression in NK cells (Table 4) . This showed that long-term persistence of functional transgene chimerism through serial transplantations was inherited with serially repopulating stem cells after a single immunoselection procedure and not dependent on a new selection step.
Discussion
The present study provides proof of principle that a clonally derived transgenic hematopoiesis can be established by a single selection step for a HSC transduced with a single copy of a simple retroviral vector. Transgene expression in mice receiving selected cells persisted with a high probability in multiple lineages for almost 2 years post gene transfer (until the termination of the study) and through serial BMTs. The transplant and selection conditions resulted in monoclonal or biclonal reconstitution of hematopoiesis, derived from HSCs that expressed relatively high levels of the transgenic cell-surface marker. The reduction of the clonal repertoire was associated with a small interindividual variability, and also with limited subclonal variegation. Almost identical results were achieved using two different variants of hCD34 as a cell-surface marker. These observations imply that the retroviral vectors used in this study contain cis-elements that mediate expression through massive clonal expansion and multilineage differentiation, provided the insertion occurred in genetic loci permissive for expression in HSCs. Earlier studies of retroviral gene marking in mice may have suggested similar hypotheses, but did not allow clear conclusions, because the assessment of clonality, unique transgene copy or multilineage differentiation was incomplete or impossible due to the experimental conditions used. 7, [9] [10] [11] [12] [13] [14] [15] [18] [19] [20] [21] [22] [23] [24] [25] 29 In contrast to the positive outcome that we observed after selection for HSCs expressing the transgene in vivo, flow cytometry-mediated sorting for high transgene expression in cultured HSCs, prior to primary BMT, did not improve long-term expression. 9 However, the loci supporting transgene expression in vitro and in vivo are not necessarily identical, because of the anticipated differences of the signals regulating survival in the recombinant environment. In the single case where a complete transgene chimerism was observed after initial sorting of cultured cells, transgene copy number, clonality and persistence through serial BMT remained unclear.
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Experiments are ongoing to determine whether the same persistence can be observed with our vector system when immunoselection is performed before primary BMT. Such a procedure is relatively well tolerated, avoids the use of mutagenic agents, and is compatible with clinically approved systems for cell processing. 15, 30, 31 Although the present study revealed an intact hematopoiesis after transplantation of immunoselected transgenic HSCs in secondary recipients, the clinical utility will be dependent on the demonstration of polyclonal reconstitution following selection prior to primary BMT. Since CD34 is expressed in clinically used HSC populations, human tCD34 cannot currently be proposed for clinical use, except when introduced into subpopulations that are CD34-negative (such as T cells). 27 For human CD34 + cells, alternative markers need to be defined, possibly even derived from xenogeneic variants of CD34.
Many clinical applications of gene-modified HSCs will require selection for clones with active transgene expression, either in vitro prior to transplantation or in vivo after reconstitution, but few will actually need multilineage expression to cure the underlying disease. It will be interesting to determine whether cis-active sequences can be defined that operate sufficiently well in HSCs while driving more lineage-specific expression in their progeny. Mutations introduced into the retroviral enhancer may shift the tropism but are unlikely to trigger specificity, because of the broad activity and redundancy of the transcription factor binding-sites presented. 28, 29, 32 Lineage-specific cis-elements of cellular genes are not +1 cells is shown in Table 4 . expected to provide efficient expression in stem cells. [33] [34] [35] Vectors with two cassettes, one expressing the selection marker under control of a broadly active enhancer/promoter and another expressing the therapeutic gene of interest under control of a lineage-restricted promoter, represent a possible solution. In this case, the therapeutic gene needs to be shielded from the unspecific activity originating from the selection cassette or the chromosomal environment. As this is difficult to achieve in retroviral vectors, the therapeutic window for background expression of a given therapeutic gene in other lineages has to be determined. The linkage of high retroviral activity in HSCs with persistence in the differentiating progeny represents a promising feature when expressing genes mediating cancer drug resistance. 1, 3, [20] [21] [22] [23] To improve the treatment of cancer patients, resistance would be required in all stages and lineages of norLeukemia mal hematopoiesis. In the present study, virtually all BM progenitors, mature myeloid or lymphoid cells, and even enucleated PLTs and RBCs expressed the transgenic protein following selection.
Expression in RBSs (lifespan about 40 days) indicates a long half-life of the marker protein. 5 However, the stable transgene expression during an observation period of 5 months in the second cohort and its long-term persistence even after tertiary BMT strongly argue for continuous de novo transcription in progenitor cells. The only lineage showing an incomplete penetrance of transgene activity in the third cohort was that of T lymphocytes (Table 4) , compatible with earlier observations and a report of a reversible downregulation of retroviral enhancer activity in resting T cells. 9, 36 The unselected controls ruled out that the transgenic cells had a growth advantage mediated by the expression of the marker gene, as serial BMT with unselected gene-modified cells resulted in a strong interindividual variability with a clear trend for declining transgene expression frequency over time. Although we obtained evidence for transgene silencing and a slight competitive disadvantage compared to untransduced cells, the present study did not address the reasons for this decline in great detail.
Our observation that a single immunoselection step may reduce the repertoire of transgenic HSCs should also raise a note of caution. We hypothesize that HSCs are generally under-represented after selection for retroviral vector expression, anticipating a lower expression of the retroviral vector in very primitive, metabolically silent stem cells compared to more mature, actively dividing progenitor cells. 5, 26, 28 Accordingly, a small clonal repertoire has previously also been noted after in vivo selection by drug resistance. 22, 23 In combination with the strong pressure for forced expansion, the limited stem cell repertoire may give rise to complications such as exhaustion or selection for cellular autonomy. 37 This concern is substantiated by the occurrence of a leukemia triggered by relatively weak genome alterations in a connected study. 4 Studies in fibroblasts revealed that a forced expansion of isolated clones promotes oncogenic progression. 38 Polyclonal reconstitution may be achieved with better culture conditions during the transduction procedure, vectors leading to higher marker expression in HSCs, and higher transplant doses. However, selection for oligoclonal transgenic hematopoiesis obviously has the striking advantage of mediating faithful multilineage transgene expression with remarkably small variability. Further studies are required to define the limits in this difficult balance.
In contrast to our observations made with HSCs, selection for retroviral vector expression in undifferentiated embryonic stem cells was complicated by silencing of transgene expression during differentiation. 39, 40 This indicates significant differences in epigenetic transgene regulation between primitive embryonic and adult stem cells, or, in general, between pregastrulation and postgastrulation cells. 41 It will be interesting to determine whether the type of control regions present in the vector, which lacked any element known to affect chromatin modulation besides a strong retroviral enhancer/promoter, 26 contributed to the promising outcome after immunoselection. Previous studies in murine HSCs used vectors with different cis-acting elements. [18] [19] [20] [21] [22] [23] [24] [25] 29 Also, features of the CD34 coding region may have contributed to stable transgene expression, as other cDNAs have been suggested to carry silencer domains. 42 Our study provides a basis to investigate the role of defined cis-acting elements and selection procedures in the maintenance of gene expression.
